ProQR Therapeutics N.V. - ADR Key Ratios
$2.09
As on 03-Sep-2026 16:00EDT
Market cap
$323 Mln
Revenue (TTM)
$19 Mln
P/E Ratio
--
P/B Ratio
3.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 330.89 | 133.27 | 12.40 | 66.16 | 82.91 |
| EBIT | 34.07 | 26.26 | -13.38 | 5.47 | 2.68 |
| Net Profit | 34.78 | 27.15 | -6.67 | 6.59 | 4.68 |
| EPS | 37.50 | 30.21 | 6.83 | 12.95 | 9.98 |
| Book Value | -- | -- | -49.87 | -15.25 | -16.57 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -270.04 | -1,348.33 | -229.99 | -259.42 | -142.20 |
| Net Margin
| -- | -- | -228.38 | -- | -- |
| Return on equity
| -47.50 | -53.51 | -65.71 | -54.14 | -40.40 |
| Return on Capital
| -36.92 | -38.78 | -- | -44.48 | -31.67 |
| Return on Assets
| -20.08 | -24.93 | -17.96 | -26.45 | -17.02 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.28 | 0.18 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
-44.48
|
-31.67
|
-34.60
|
-43.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-65.71
Lower than Peers by 25.40
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-65.71
|
-54.14
|
-40.40
|
-47.95
|
-64.10
|
|
Peer Median
|
-40.31
|
--
|
--
|
--
|
--
|
ROA
-17.96
Higher than Peers by 10.94
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-17.96
|
-26.45
|
-17.02
|
-16.78
|
-30.59
|
|
Peer Median
|
-28.90
|
--
|
--
|
--
|
--
|
EBIT Margin
-229.99
Higher than Peers by 263.71
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-229.99
|
-259.42
|
-142.20
|
-408.50
|
-1,641.10
|
|
Peer Median
|
-493.71
|
--
|
--
|
--
|
--
|
Net Margin
-228.38
Higher than Peers by 162.56
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-228.38
|
-265.21
|
-146.86
|
-431.67
|
-1,792.54
|
|
Peer Median
|
-390.94
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
12.40
Higher than Peers by 6.09
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
12.40
|
-0.19
|
1.90
|
0.81
|
1.69
|
|
Peer Median
|
6.30
|
--
|
--
|
--
|
--
|
EBIT Growth
-13.38
Lower than Peers by 5.66
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-13.38
|
-47.43
|
-1.03
|
54.88
|
-2.98
|
|
Peer Median
|
-7.73
|
--
|
--
|
--
|
--
|
Net Profit Growth
-6.67
Higher than Peers by 17.16
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-6.67
|
-45.95
|
1.27
|
56.35
|
-6.07
|
|
Peer Median
|
-23.83
|
--
|
--
|
--
|
--
|
EPS Growth
6.83
Higher than Peers by 8.08
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
6.83
|
-0.16
|
0.05
|
0.57
|
0.02
|
|
Peer Median
|
-1.25
|
--
|
--
|
--
|
--
|
Book Value Growth
-3.20
Higher than Peers by 1.38
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
-3.20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-4.58
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
0.28
|
0.18
|
0.48
|
0.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.06
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
0.06
|
0.09
|
0.05
|
0.04
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.49
Lower than Peers by 4.34
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
3.49
|
3.09
|
3.95
|
3.54
|
7.36
|
|
Peer Median
|
7.83
|
--
|
--
|
--
|
--
|
Quick Ratio
3.49
Lower than Peers by 4.34
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
3.49
|
--
|
--
|
3.54
|
7.36
|
|
Peer Median
|
7.83
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
-45.75
|
-24.96
|
-22.12
|
-11.50
|
|
Peer Median
|
-40.26
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.03
Lower than Peers by 18.30
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
10.03
|
39.10
|
11.10
|
21.50
|
1,699.64
|
|
Peer Median
|
28.33
|
--
|
--
|
--
|
--
|
Asset Turnover
0.08
Higher than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
0.08
|
0.10
|
0.12
|
0.04
|
0.02
|
|
Peer Median
|
0.02
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
96.49
|
33.81
|
1,751.84
|
3,151.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
--
|
--
|
9.39
|
20.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
25.78
|
--
|
2,900.45
|
46.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
--
|
--
|
--
|
-1,139.22
|
3,124.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|